Diabetes
Refine Search
Biotechnology
Privately-held Canadian firm Parvus Therapeutics has entered into a license and collaboration agreement with Swiss pharma giant Novartis to hunt for new diabetes treatments. 20 April 2017
Pharmaceutical
Danish diabetes giant Novo Nordisk has billed its new treatment as a ‘next generation insulin’ as the product arrives in major European markets. 11 April 2017
Pharmaceutical
Abdi İbrahim, a leading Turkish drugmaker, has commenced exports to Azerbaijan and Georgia from its Kazakhstan company, Abdi Ibrahim Global Pharm, which houses pharmaceutical production facilities. 11 April 2017
Generics
Japan’s largest drugmaker Takeda Pharmaceutical has sold seven off-patent products in Japan to Teva Takeda Yakuhin. 10 April 2017
Pharmaceutical
Shares in US pharma giant Merck & Co slipped in the morning’s trading on news that the US Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the company’s Supplemental New Drug Applications for Januvia (sitagliptin) and its two Janumet (sitagliptin and metformin HCl) formulations. 7 April 2017
Pharmaceutical
A stellar performance from the diabetes drug Jardiance (empagliflozin) is keeping Germany’s Boehringer Ingelheim firmly on the path to growth as it prepares for the loss of patent protection on its chronic obstructive pulmonary disease blockbuster Spiriva (tiotropium). 6 April 2017
Pharmaceutical
For almost a century, Danish diabetes care giant Novo Nordisk has been developing insulins and treatments for people with diabetes. 6 April 2017
Pharmaceutical
Danish diabetes giant Novo Nordisk has presented findings from a post hoc analysis of Phase III trial data which showed greater efficacy for semaglutide in comparison with sitagliptin, the generic name for Januvia, from Merck & Co. 3 April 2017
Pharmaceutical
Diabetes has shifted from being a chronic condition that affects a few, to being a global epidemic that is responsible for considerable morbidity and mortality worldwide. 3 April 2017
Pharmaceutical
Mitsubishi Tanabe Pharma and Daiichi Sankyo have agreed to expand their strategic alliance in the field of diabetes and have entered into a marketing alliance agreement for MT-2412. 30 March 2017
Pharmaceutical
Danish pharmaceutical company Novo Nordisk has announced that its new fast-acting mealtime insulin Fiasp (insulin aspart) has been launched in Canada. 27 March 2017
Pharmaceutical
US pharma major Eli Lilly is to invest $850 million in its US operations in 2017, the company announced on Friday. 24 March 2017
Pharmaceutical
As stipulated under the Indian Drugs Price Control Order (DPCO), drug pricing regulator the National Pharmaceutical Pricing Authority (NPPA) has slashed the price of cancer drugs by up to 86% since a year ago, with several more cuts in the offing, reports The Pharma Letter’s India correspondent. 20 March 2017
Pharmaceutical
Anglo-Swedish pharmaceutical firm AstraZeneca today announced results from a study that analyzed real-world evidence to evaluate a newer class of diabetes medicines, SGLT-2 inhibitors. 20 March 2017
Pharmaceutical
Recent figures confirm a continuous rise in rates of overweight and obesity. Since the 1980s, the prevalence of both conditions has more than doubled worldwide. In 2014, more than half of the adult population was tackling weight issues, with 13% living with obesity and 39% being overweight. 20 March 2017
Pharmaceutical
Sanofi and software designer Voluntis have announced a global alliance to deliver digital insulin titration solutions featuring a mobile phone application for type 2 diabetes patients treated with basal insulin to help with self-management and enable remote monitoring by healthcare teams. 15 March 2017
Biotechnology
Takeda Pharmaceutical has joined forces with Innovation Network Corporation of Japan (INCJ) and Medipal Holdings to jointly invest a total of 10 billion yen (~$87 million) to establish a new company, which will be named Scohia Pharma. 15 March 2017
Pharmaceutical
A new health economic analysis of two Phase IIIb trials has demonstrated that Tresiba (insulin degludec) is a cost-effective option for people living with type 1 and type 2 diabetes compared to insulin glargine U100 (Lantus). 9 March 2017
Pharmaceutical
The US Food and Drug Administration has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes. 7 March 2017
Pharmaceutical
Jakob Riis, executive vice president, head of North America Operations and president of Novo Nordisk Inc, has resigned, Danish diabetes care giant Novo Nordisk announced this morning. 1 March 2017
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze